{
    "2018-04-10": [
        [
            {
                "time": "2018-03-15",
                "original_text": "AbbVie's RA Candidate Meets Primary Endpoints in Phase III",
                "features": {
                    "keywords": [
                        "RA",
                        "candidate",
                        "Phase III",
                        "primary endpoints"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-05",
                "original_text": "Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie",
                "features": {
                    "keywords": [
                        "ex-dividend",
                        "American Eagle",
                        "Buckle",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "retail",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "FDA needs more time to review AbbVie, Neurocrine's uterine pain drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "review",
                        "AbbVie",
                        "Neurocrine",
                        "uterine pain drug"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "FDA extends review for AbbVie, Neurocrine's uterine pain drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "extends",
                        "review",
                        "AbbVie",
                        "Neurocrine",
                        "uterine pain drug"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-07-15",
                "original_text": "AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain",
                "features": {
                    "keywords": [
                        "PDUFA",
                        "target date",
                        "Q3",
                        "Elagolix",
                        "Endometriosis-Associated Pain"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-25",
                "original_text": "See what the IHS Markit Score report has to say about AbbVie Inc.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "report",
                        "AbbVie Inc."
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-10",
                "original_text": "ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs",
                "features": {
                    "keywords": [
                        "SELECT-COMPARE",
                        "Goals",
                        "ATOMIK",
                        "Flops",
                        "VTVT",
                        "Down",
                        "After-Hrs"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            }
        ]
    ]
}